知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

65 条记录 (耗时 0.019 秒)

    Phase offset determination in magnetic resonance imaging
    3.
    发明授权
    Phase offset determination in magnetic resonance imaging 有权

    公开(公告)号：US10605885B2

    公开(公告)日：2020-03-31

    申请号：US16323653

    申请日：2017-06-09

    申请人： MEDIZINISCHE UNIVERSITÄT WIEN

    发明人： Simon Robinson ,  Korbinian Eckstein

    IPC分类号： G01V3/00 ,  G01R33/565 ,  A61B5/055 ,  A61B5/00

    摘要： The disclosed subject matter relates to a method for determining phase offsets in a complex-valued image in Magnetic Resonance Imaging, including the steps of, immobilising an object and acquiring a first image thereof at a predetermined first echo time and a second image thereof at a predetermined second echo time, the first and second images being separated into first and second magnitude images and first and second phase images, respectively, wherein a ratio between said first echo time and said second echo time is chosen to be n:(n+1), n being a positive integer; generating, pixel by pixel, a phase evolution image; and subtracting, pixel by pixel, an n-fold of the phase evolution image from the first phase image to obtain a phase offset image containing said phase offsets.

    Method for the Detection of an IgM Antibody Specific for a Flavivirus in a Sample
    4.
    发明申请
    Method for the Detection of an IgM Antibody Specific for a Flavivirus in a Sample 审中-公开

    公开(公告)号：US20190170750A1

    公开(公告)日：2019-06-06

    申请号：US16307710

    申请日：2017-06-02

    申请人： MEDIZINISCHE UNIVERSITÄT WIEN

    发明人： Franz X. HEINZ ,  Karin STIASNY

    IPC分类号： G01N33/569

    摘要： Disclosed is a method for the detection of an IgM antibody specific for a flavivirus in a sample, comprising the steps of (a) contacting the sample with a solid support comprising immobilised IgM-binding molecules, (b) allowing binding of IgM antibodies in the sample to the IgM binding molecules on the solid support so that the IgM antibodies are also immobilised on the solid support, and (c) detecting IgM antibodies specific for a flavivirus by allowing binding of a complex comprising (i) an antiparallel dimer of soluble flavivirus Protein E (sE) and (ii) a marker and identifying the binding of the complex to the specific flavivirus IgM antibody by detecting the marker; and a kit suitable for performing the method.

    CELL CULTURE MODEL OF VASCULAR CALCIFICATION
    5.
    发明申请
    CELL CULTURE MODEL OF VASCULAR CALCIFICATION 审中-公开

    公开(公告)号：US20180282700A1

    公开(公告)日：2018-10-04

    申请号：US15768542

    申请日：2016-10-13

    申请人： Medizinische Universität Wien

    发明人： Karin Macfelda ,  Barbara Kapeller ,  Alexander Holly ,  Roman Lieber

    IPC分类号： C12N5/071 ,  G01N33/50

    摘要： The present invention relates to a cell culture model of vascular calcification, comprising a first type of cultured vascular smooth muscle cells and a second type of cultured vascular smooth muscle cells, wherein the first type and the second type of vascular smooth muscle cells originate from blood vessels having a different diameter, e.g., from the human aorta and from a human coronary artery, respectively. This model allows to generate and analyze vascular calcification processes, including early calcification processes, in an advantageously simple and cost-effective way and with high sensitivity. It can further be used to identify and examine compounds capable of halting, inhibiting or reversing such vascular calcification processes.

    PERSONALIZED THERAPY OF INFLAMMATION-ASSOCIATED CANCER USING METHODS OF ASSESSING THE SUSCEPTIBILITY OF A SUBJECT TO THE TREATMENT WITH EGFR INHIBITORS/ANTAGONISTS
    8.
    发明申请
    PERSONALIZED THERAPY OF INFLAMMATION-ASSOCIATED CANCER USING METHODS OF ASSESSING THE SUSCEPTIBILITY OF A SUBJECT TO THE TREATMENT WITH EGFR INHIBITORS/ANTAGONISTS 审中-公开

    公开(公告)号：US20170184595A1

    公开(公告)日：2017-06-29

    申请号：US15312252

    申请日：2015-05-21

    申请人： Medizinische Universität Wien

    发明人： Maria SIBILIA

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57419 ,  G01N33/57438 ,  G01N2333/71 ,  G01N2800/50 ,  G01N2800/7095

    摘要： The present invention relates to in vitro methods of assessing the susceptibility or responsiveness of a subject to the treatment with an epidermal growth factor receptor (EGFR) inhibitor/antagonist, wherein the subject has been diagnosed or suspected of suffering from inflammation-associated. These methods comprise determining the level of expression of EGFR in myeloid cells in a sample from the subject, wherein an expression of EGFR in the myeloid cells is indicative of the subject being susceptible to the treatment with an EGFR inhibitor/antagonist. The invention also relates to EGFR inhibitors/antagonists for use in the treatment or amelioration of inflammation-associated cancer. The invention furthermore provides in vitro methods of prognosing the survival time, progression-free survival time or disease course of a subject that has been diagnosed or suspected of suffering from from inflammation-associated cancer. In addition thereto, the invention relates to in vitro diagnostic methods of assessing the proneness of a subject to develop inflammation-associated cancer in which the expression of EGFR is determined in myeloid cells from the subject.

    SOLUBLE AXL RECEPTOR TYROSINE KINASE IN THE DIAGNOSIS OF CANCER
    9.
    发明申请
    SOLUBLE AXL RECEPTOR TYROSINE KINASE IN THE DIAGNOSIS OF CANCER 审中-公开

    公开(公告)号：US20170146540A1

    公开(公告)日：2017-05-25

    申请号：US15126661

    申请日：2015-03-18

    申请人： Medizinische Universität Wien

    发明人： Wolfgang MIKULITS ,  Patrick REICHL

    IPC分类号： G01N33/574

    摘要： The present invention relates to a method for assessing whether a patient suffers from cancer, such as hepatocellular carcinoma, or is prone to suffering from cancer, such as hepatocellular carcinoma, wherein said method comprises determining the amount of soluble AXL in a sample from the patient. The patient is assessed to suffer from cancer or to be prone to suffering from cancer when the amount of soluble AXL is increased in comparison to a control. The present invention relates to the use of soluble AXL for assessing whether a patient suffers from cancer, such as hepatocellular carcinoma, or is prone to suffering from cancer, such as hepatocellular carcinoma. Also a kit for use in the methods of the present invention is provided.

    AMIDOPHENOXYPROPANOLAMINES
    10.
    发明申请
    AMIDOPHENOXYPROPANOLAMINES 审中-公开
    氨基羟基丙醇胺

    公开(公告)号：US20160318887A1

    公开(公告)日：2016-11-03

    申请号：US15204585

    申请日：2016-07-07

    申请人： MEDIZINISCHE UNIVERSITÄT WIEN

    发明人： Hubert Gstach ,  Peter Chiba ,  Matthias Mastalir

    IPC分类号： C07D295/088 ,  C07C235/66 ,  C07D229/02 ,  C07D211/14 ,  C07C235/60 ,  C07C235/64

    CPC分类号： C07D295/088 ,  C07C235/60 ,  C07C235/64 ,  C07C235/66 ,  C07C237/28 ,  C07C2601/02 ,  C07C2601/18 ,  C07C2601/20 ,  C07C2603/74 ,  C07D211/14 ,  C07D211/18 ,  C07D229/02

    摘要： The use of compounds of formula wherein R2, R3, R4, R5, R6 and R7 have several meanings, for the treatment of disorders mediated by protozoan organisms, novel compounds of the above formula and intermediates for the preparation of such compounds, pharmaceutical compositions comprising such novel compounds, a method of treating disorders mediated by protozoan organisms comprising administering such compounds, optionally together with a second drug substance, to a subject in need thereof and the use of such compounds, whenever comprising a photoaffinity label, for the identification of the molecular target(s) of arylamino alcohol antimalarials.

    摘要翻译： 其中R 2，R 3，R 4，R 5，R 6和R 7具有多种含义，用于治疗由原生动物生物介导的病症，上式的新化合物和用于制备这些化合物的中间体，包含这些新化合物的药物组合物， 治疗由原生动物生物介导的病症，包括将任选地与第二药物物质一起给予有此需要的受试者，并且每当包含光亲和标记物时，使用这些化合物来鉴定分子靶标 芳基氨基醇抗疟药。